Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DH42RF
|
|||
| Drug Name |
PD-L1 t-haNK
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
ImmunityBio; NantKwest
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | . | [1] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | Costimulation by the CD28 family | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04050709) QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.